

## Market Data

### Genetic Technologies

Nasdaq: **GENE**

ASX: **GTG**

Fiscal Year June

Industry Medical  
Diagnostics

Recent Price \$1.16

Market Cap \$17.9M

ADS Out. 15.4M

Avg. Volume  
(30-day) 24,470

Revenue (ttm) \$4.8M

Cash (mrq) \$8.2M

Debt (mrq) \$0


*Price data as of December 9, 2022*

*Financial data in USD based on  
AUD/USD exchange rate on June  
30, 2022*

gtglabs.com

## Company Overview

Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company's lead products, 'GeneType for Breast Cancer' and 'GeneType for Colorectal Cancer', are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and is now rolling out its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisitions of EasyDNA and AffinityDNA has significantly accelerated the Company's commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.



## Value Proposition


Dual-listed on Nasdaq and ASX, Genetic Technologies' patented tests are designed to predict an individual's risk of developing chronic disease, enabling early detection and reducing the need for expensive, late-stage care. Chronic disease accounts for an estimated 84% of global healthcare spending, which is expected to reach \$8.7 trillion by 2020. The Company has brought four tests to market, including its recently launched, game-changing Multi-Test, which covers up to 70% of mortalities and morbidities. Through its August 2021 acquisition of EasyDNA and its May 2022 acquisition of AffinityDNA, Genetic Technologies has significantly accelerated its entrance into the multi-billion-dollar consumer genomics market. In addition to an established revenue stream (\$4.6M in CY20), EasyDNA provides Genetic Technologies the opportunity to leverage an existing global direct-to-consumer marketing channel (operating 70 websites servicing 40 countries), while AffinityDNA further augments this expansive global distribution network.

## Commercialization Pathways

**Medical – Business to Business  
(B2B)**

**Consumer initiated testing (CIT)  
with medical supervision**

**Direct to consumer testing (DTC)  
with no medical supervision**



## Investment Highlights

- **Leader in the development and commercialization of genetic risk assessment tests**
  - Launched new 'GeneType' tests for breast and colorectal cancer
  - Tests allow providers to target limited resources to patients most in need
  - First-to-market clinical application; most genetic testing remains non-clinical and consumer oriented (genealogy, paternity, etc.)
  - Soft launch in US began in Q1 2020; full online sales began in Q3 2020
  - Launched COVID-19 risk test in 2021; partnered with Infinity BiologiX for US sales
- **Recent acquisitions expected to accelerate consumer channel growth**
  - EasyDNA (Aug 2021): Provides for global expansion in consumer genomics in 40 countries with established sales platform and infrastructure
  - AffinityDNA (May 2022): Direct-to-consumer eCommerce business will provide incremental distribution channels to the Company's EasyDNA brand
- **Launched game-changing Multi-Test**
  - The Multi-Test companion diagnostic helps identify risk of serious disease for up to 70% of mortalities and morbidities
  - First phase of launch to include breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease, and Type 2 diabetes; second phase of launch to add melanoma, pancreatic cancer, and atrial fibrillation
- **Respected collaborators accelerate development and validate clinical use**
  - Collaborations led to NHMRC grant (Australia's leading medical research funding organization)
  - Research collaborations with Memorial Sloan Kettering Cancer Center and University of Cambridge announced in February 2019
  - Multi-year agreement with The Translational Genomics Research Institute
- **Global opportunity; initially targeting US, Australia, and China**
  - Global healthcare spending exceeds \$8 trillion annually